Pharmacokinetics and elimination of quetiapine, venlafaxine, and trazodone during pregnancy and postpartum

Journal of Clinical Psychopharmacology

Volumn 27, Issue 6, 2007, Pages 720-722

  Klier, Claudia M ^a   Mossaheb, Nilufar ^a   Saria, Alois ^b   Schloegelhofer, Monika ^a   Zernig, Gerald ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

QUETIAPINE; TRAZODONE; VENLAFAXINE; CYCLOHEXANOL DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADOLESCENT; ALCOHOL ABUSE; BIPOLAR II DISORDER; CASE REPORT; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; FEMALE; FETUS RISK; HUMAN; LETTER; PREGNANCY; PRENATAL DRUG EXPOSURE; PRENATAL SCREENING; PRIORITY JOURNAL; PUERPERIUM; BIPOLAR DISORDER; BLOOD; METABOLISM; PREGNANCY OUTCOME; SLEEP DISORDER;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CYCLOHEXANOLS; DIBENZOTHIAZEPINES; FEMALE; HUMANS; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTERS; SLEEP DISORDERS; TRAZODONE;

EID: 39649097002     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31815a57d8     Document Type: Letter

References (13)

1. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005; 365(9458):451-453.
2. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579-587.
3. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005;66(4): 444-449.
4. Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology. 2003;61(6 suppl 2):S35-S42.
5. Newport DJ, Viguera AC, Beach AJ, et al. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry. 2005; 162(11):2162-2170.
6. Pennell PB, Newport DJ, Stowe ZN, et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology. 2004; 62(2):292-295.
7. Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry. 1993;150(10):1541-1542.
8. Hostetter A, Stowe ZN, Strader JR Jr, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety. 2000;11(2):51-57.
9. DeVane CL, Stowe ZN, Donovan JL, et al. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol. 2006;20(4 suppl):54-59.
10. Aichhorn W, Marksteiner J, Walch T, et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentration. Int Clin Psychopharmacol. 2006;21(2):81-85.
11. Klier CM, Schmid-Siegel B, Schaefer MR, et al. St. John's wort (Hypericum perforatum) and breastfeeding: concentrations of hyperforin in nursing Infants and breast milk. J Clin Psychiatry. 2006;67(2):305-309.
12. Aichhorn W, Weiss U, Marksteiner J, et al. Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol. 2005;19(4):395-401.
13. Kirschbaum KM, Mueller MJ, Zernig G, et al. Therapeutic monitoring of aripiprazole using HPLC with column-switching. Clin Chem. 2005;51:1718-1721.